Australia approves single-dose vaccine to protect koalas from chlamydia
Researchers say the newly approved vaccine could cut koala mortality by as much as 65%; initial rollout to begin next year amid calls for more funding
Australia has approved and begun funding a single-dose vaccine designed to protect wild koalas against chlamydia, a disease that researchers say is a leading cause of death and infertility in the species.
The vaccine, developed over more than a decade by University of the Sunshine Coast microbiologist Peter Timms and colleagues, is part of a broader government effort to bolster a struggling koala population that conservationists estimate at roughly 60,000 in the wild. The federal government has set aside about AU$495,000 from a AU$76 million koala package; most of that money is earmarked for habitat restoration and a national monitoring program.
Chlamydia is commonly transmitted by direct contact during mating and from mother to joey at birth. In koalas, the bacterial infection can cause severe urinary tract disease, blindness and infertility, and has been blamed for more than half of wild koala deaths in some areas. Infection rates in parts of Queensland and New South Wales have been reported to spike between 50% and 70%.
Timms and his research partner, microbiologist Samuel Phillips, said the vaccine was intentionally formulated as a single dose so animals would not need to be trapped and returned for repeat treatment. Phillips said it took 15 years to refine the formula to include three chlamydia protein targets and an adjuvant that boosts immune response.
"It offers three levels of protection — reducing infection, preventing progression to clinical disease and, in some cases, reversing existing symptoms," Timms said. The researchers estimate the vaccine could reduce chlamydia-related mortality among wild koalas by as much as 65%.
The team plans to release about 500 doses early next year and has reported interest from wildlife hospitals. Phillips said additional funding will be required to scale production and deliver broader protection: "We estimate that they’ll need at least 1,000 to 2,000 doses per year, and that’s not including the program to go out and try and protect koala populations."
Beyond disease, koalas face ongoing threats from habitat loss, deforestation and climate-linked bushfires. The species was heavily hunted for its fur in the early 20th century before protections were enacted; more recently, large bushfires and land clearing have fragmented habitat and increased mortality.
In April, authorities culling injured and sick koalas in a fire-affected region used low-flying helicopters, an action that conservation groups said led to hundreds of animals being killed and left many healthy joeys orphaned. Wildlife advocates and researchers say disease control, habitat restoration and coordinated monitoring are all necessary components of a recovery strategy.
The vaccine approval marks a significant scientific milestone for wildlife health, but researchers and conservation groups have stressed that the measure is not a standalone solution. Wider distribution, sustained funding and ongoing surveillance will be necessary for the vaccine to meaningfully reverse population declines and reduce the long-term impacts of chlamydia on koala reproduction and survival.
